Drug trio found to block tumour resistance in pancreatic cancer
Summary
Drug Target Review reports that a triple-drug combination can induce complete regression and prevent resistance in pancreatic cancer models by simultaneously inhibiting KRAS downstream (RAF1), upstream (EGFR), and parallel (STAT3) signaling. The therapy uses RMC-6236, Afatinib, and SD36, with efficacy in orthotopic mouse models and patient-derived tumor xenografts, and a favorable safety profile in animals. The article also discusses automation's role in discovery and data-driven systems that improve reproducibility and decision speed in R&D.